8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
West Pharmaceutical raises 2026 sales and adjusted EPS guidance after strong Q2
Filed with the SEC on · Summarized by InvestorsBot
West Pharmaceutical reported second-quarter 2026 sales of $872.3 million, up 13.8% year over year, and adjusted diluted EPS of $2.37, up 28.8%, with organic sales growth of 12.7%. The company raised full-year 2026 sales guidance to $3.345 billion-$3.380 billion and adjusted diluted EPS guidance to $8.85-$9.05, while reporting $128.0 million in first-half free cash flow and $454.3 million spent repurchasing shares.